Early Detection of Acute Myeloid Leukemia (AML) Using YOLOv12 Deep Learning Model

The headline accuracy figure deserves a closer look: 99.3% on a controlled microscopy dataset is not the same as performance in a messy clinical lab, where staining variation, imaging equipment differences, and rare cell morphologies routinely degrade model reliability. The paper's contribution is methodological, showing that a real-time object-detection model can be adapted for cytology, not that the clinical problem is solved.

This sits within a growing cluster of high-stakes medical ML work. The MADE benchmark paper covered here recently highlighted exactly this tension: strong aggregate accuracy metrics can mask serious reliability gaps on rare or ambiguous cases, and uncertainty quantification is increasingly treated as a requirement rather than a bonus in healthcare applications. That framing applies directly here. YOLOv12 is an object-detection architecture built for speed, and adapting it for cytology is genuinely interesting, but the AML paper does not appear to address confidence calibration or out-of-distribution robustness, which the MADE authors flagged as critical gaps.

Watch whether the authors or an independent group validate this approach on a multi-site dataset with varied staining protocols. If accuracy holds above 95% under those conditions, the clinical case becomes substantially stronger.